Provectus Biopharmaceuticals Inc PVCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PVCT is a good fit for your portfolio.
News
-
Provectus Biopharmaceuticals Announces Investor Webinar for 2024 Annual Meeting of Stockholders
-
Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting
-
Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting
-
Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)
Trading Information
- Previous Close Price
- $0.11
- Day Range
- $0.10–0.11
- 52-Week Range
- $0.06–0.22
- Bid/Ask
- $0.10 / $0.11
- Market Cap
- $44.05 Mil
- Volume/Avg
- 89,918 / 222,509
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes (HXs). Its lead HX molecule is named rose bengal sodium. The Company’s proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the drug product candidates of its current clinical development programs and the preclinical formulations of its current drug discovery programs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 4
- Website
- https://www.provectusbio.com
Comparables
Valuation
|
Metric
|
PVCT
|
ABOS
|
RIGL
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.80 | — |
Price/Sales | — | — | 1.56 |
Price/Cash Flow | — | — | — |
Price/Earnings
PVCT
ABOS
RIGL
Financial Strength
|
Metric
|
PVCT
|
ABOS
|
RIGL
|
|---|---|---|---|
Quick Ratio | 0.00 | 29.83 | 1.05 |
Current Ratio | 0.12 | 30.20 | 1.26 |
Interest Coverage | −11.20 | — | −1.95 |
Quick Ratio
PVCT
ABOS
RIGL
Profitability
|
Metric
|
PVCT
|
ABOS
|
RIGL
|
|---|---|---|---|
Return on Assets (Normalized) | −182.19% | −19.28% | −7.25% |
Return on Equity (Normalized) | — | −21.04% | — |
Return on Invested Capital (Normalized) | — | −24.75% | −11.44% |
Return on Assets
PVCT
ABOS
RIGL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Rdnlzsmdw | Cmwc | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Hrmlygg | Wmxtb | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vwhdbgmpk | Ppscjt | $118.7 Bil | |||
| Moderna Inc
MRNA
| Xyrxydzf | Dcryt | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mmpgbyvpx | Rgdsc | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Zyjncxm | Fqkbb | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Smnsrzf | Mbk | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Jwcspwbt | Jhzqk | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Mpgdrsf | Brls | $15.0 Bil | |||
| Incyte Corp
INCY
| Gycpwbg | Jchlp | $13.5 Bil |